Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1099
- Registration Number
- NCT00241124
A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3790
- Registration Number
- NCT00241137
Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 392
- Registration Number
- NCT00241085
Effect of Valsartan on Carotid Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2015-12-08
- Lead Sponsor
- Emory University
- Target Recruit Count
- 120
- Registration Number
- NCT00208767
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
Rationale and Design for Shiga Microalbuminuria Reduction Trial
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2006-04-27
- Lead Sponsor
- Shiga University
- Target Recruit Count
- 160
- Registration Number
- NCT00202618
- Locations
- 🇯🇵
Shiga University of Medical Science, Otsu, Shiga, Japan
Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- KVT-Study Group
- Target Recruit Count
- 312
- Registration Number
- NCT00190580
- Locations
- 🇯🇵
St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 20
- Registration Number
- NCT00185055
VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With Microalbuminuria
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 134
- Registration Number
- NCT00171067
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 265
- Registration Number
- NCT00171041
- Locations
- 🇺🇸
Novartis Pharmaceuticals, E.Hanover, New Jersey, United States
Antiproteinuric Effect of Valsartan and Lisinopril
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 124
- Registration Number
- NCT00171574
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.